Published in Br J Clin Pharmacol on October 01, 1980
Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists. Br J Clin Pharmacol (1983) 0.91
Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist. Br J Clin Pharmacol (1985) 0.83
Comparison of the haemodynamic effects of bucindolol, propranolol and pindolol in healthy volunteers. Br J Clin Pharmacol (1985) 0.76
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
A method for the fluorimetric determination of 4-(2-hydroxy-3-isopropylaminopropoxy)-indole (LB46), a beta-blocking agent, in plasma and urine. Experientia (1969) 2.31
Intravenously administered isoproterenol sulfate dose-response curves in man. Arch Intern Med (1972) 2.23
Beta-adrenergic receptor blocking drugs in hypertension. Drugs (1974) 2.18
Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs. Clin Pharmacokinet (1976) 2.12
Studies of the absorption and removal of propranolol in hypertensive patients during therapy. Circulation (1975) 1.92
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
The use of beta-adrenergic receptor blocking drugs in dysrhythmias. Prog Cardiovasc Dis (1969) 1.47
Quantitative determination of metoprolol in plasma and urine by gas chromatography. Acta Pharmacol Toxicol (Copenh) (1975) 1.47
Plasma levels and effects of metoprolol on blood pressure and heart rate in hypertensive patients after an acute dose and between two doses during long-term treatment. Clin Pharmacol Ther (1975) 1.44
A sensitive gas chromatographic method for the determination of propranolol in human plasma. J Chromatogr (1973) 1.34
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation (1975) 1.24
Hypertension: which beta-blocker? Drugs (1976) 1.11
Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol. J Clin Invest (1973) 1.10
Comparative effects of beta adrenergic blocking drugs. Thorax (1975) 1.04
The relationship of plasma levels of pindolol in hypertensive patients to effects on blood pressure, plasma renin and plasma noradrenaline levels. Clin Exp Pharmacol Physiol (1975) 0.96
Activation and blockade of beta adrenoceptors in common cardiac disorders. Br Med Bull (1973) 0.85
Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol (1978) 0.83
Drug interactions with cimetidine. Clin Pharmacokinet (1982) 2.49
Pharmacokinetic studies of practolol, a beta adrenergic antagonist, in man. Clin Pharmacol Ther (1973) 2.14
Impaired cimetidine absorption due to antacids and metoclopramide. Eur J Clin Pharmacol (1981) 1.86
Pharmacokinetics of pindolol in man. Eur J Clin Pharmacol (1974) 1.46
Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet (1980) 1.42
Is radical scavenging necessary in the treatment of inflammatory bowel disease? Gastroenterology (1991) 1.39
[The duodenojejunal flexure--a gap in the routine diagnosis of gastrointestinal bleeding]. Dtsch Med Wochenschr (1999) 1.38
The effect of pindolol on exercise-induced cardiac acceleration in relation to plasma levels in man. Clin Pharmacol Ther (1975) 1.33
Clinical pharmacokinetics of cimetidine. Clin Pharmacokinet (1984) 1.32
Cimetidine for anastomotic ulcers after partial gastrectomy. A randomized controlled trial. N Engl J Med (1979) 1.32
Omeprazole inhibits oxidative drug metabolism. Studies with diazepam and phenytoin in vivo and 7-ethoxycoumarin in vitro. Gastroenterology (1985) 1.29
Cimetidine plasma concentration-response relationships. Clin Pharmacol Ther (1981) 1.29
Effect of smoking on duodenal ulcer healing with cimetidine and oxmetidine. Gut (1982) 1.22
Disposition of quercetin in man after single oral and intravenous doses. Eur J Clin Pharmacol (1975) 1.21
Objective and subjective evaluation of photic phenomena after monofocal and multifocal intraocular lens implantation. Ophthalmology (1999) 1.15
Phenytoin: pharmacokinetics and bioavailability. Clin Pharmacol Ther (1976) 1.14
Pharmacodynamic studies of beta adrenergic antagonism induced in man by propranolol and practolol. J Clin Invest (1973) 1.10
Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther (1983) 1.09
Plasma protein binding of valproic acid in healthy subjects and in patients with renal disease. Br J Clin Pharmacol (1978) 1.08
Inhibition of human liver cytochrome P-450 by omeprazole. Br J Clin Pharmacol (1986) 1.06
Spironolactone. Am Heart J (1978) 1.05
Pharmacokinetics of ketamine in man. Anaesthesist (1975) 1.03
Effect of in vivo elevation of free fatty acids on protein binding of drugs. Pharmacology (1974) 1.02
Pharmacokinetics and bioavailability of cimetidine in gastric and duodenal ulcer patients. Clin Pharmacokinet (1980) 1.02
HJV gene mutations in European patients with juvenile hemochromatosis. Clin Genet (2005) 0.98
Does smoking interfere with the effect of histamine H2-receptor antagonists on intragastric acidity in man? Gut (1987) 0.97
Clofibrate disposition in renal failure and acute and chronic liver disease. Eur J Clin Pharmacol (1979) 0.95
Effect of portacaval shunt on the disposition of drugs with and without first-pass effect. J Pharmacol Exp Ther (1975) 0.94
Single- and multiple-dose kinetics of intravenous digoxin. Clin Pharmacol Ther (1980) 0.93
Intraocular pressure after small incision cataract surgery: temporal sclerocorneal versus clear corneal incision. J Cataract Refract Surg (2001) 0.92
Pharmacokinetics of drugs in patients with the nephrotic syndrome. J Clin Invest (1975) 0.92
Drug protein binding and the nephrotic syndrome. Clin Pharmacokinet (1976) 0.92
Inflammation after sclerocorneal versus clear corneal tunnel phacoemulsification. Ophthalmology (2000) 0.91
Influence of thyroid status on plasma half-life of antipyrine in man. N Engl J Med (1974) 0.90
Omeprazole inhibits elimination of diazepam. Lancet (1984) 0.90
Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data. Eur J Clin Pharmacol (1982) 0.90
Clofibrate kinetics after single and multiple doses. Clin Pharmacol Ther (1978) 0.89
Contrast sensitivity and glare disability by halogen light after monofocal and multifocal lens implantation. Br J Ophthalmol (2000) 0.88
In vivo interactions between H2-receptor antagonists and ethanol metabolism in man and in rats. Hepatology (1985) 0.88
[Familial dwarfism with disproportionately high vertebral bodies]. Humangenetik (1972) 0.87
Effect of clofibrate on the metabolism of bilirubin, bromosulphophthalein and indocyanine green and on the biliary lipid composition in Gilbert's syndrome. Clin Sci (Lond) (1984) 0.87
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension. Eur J Clin Pharmacol (1984) 0.87
Impairment of digoxin clearance by coadministration of quinidine. J Clin Pharmacol (1981) 0.87
Cimetidine interaction with liver microsomes in vitro and in vivo. Involvement of an activated complex with cytochrome P-450. Biochem Pharmacol (1985) 0.86
Dose-independent pharmacokinetics of digoxin in humans. Am Heart J (1978) 0.86
Disposition of valproic acid in man. Eur J Clin Pharmacol (1977) 0.85
Gastric acid inhibition and oxmetidine kinetics in duodenal ulcer. Clin Pharmacol Ther (1982) 0.83
Drugs other than H2-receptor antagonists as clinically important inhibitors of drug metabolism in vivo. Pharmacol Ther (1987) 0.83
[Purification and characterization of a 3'-phosphoadenylylsulfate: steroid sulfotransferase from human liver]. Biochim Biophys Acta (1970) 0.83
Single and multiple dose pharmacokinetics of pindolol. Eur J Clin Pharmacol (1978) 0.83
Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. Am Heart J (1980) 0.82
Sensitive high-performance liquid chromatographic method for the determination of metronidazole and metabolites. J Chromatogr (1983) 0.82
Superoxide inhibition following different stimuli of respiratory burst and metabolism of aminosalicylates in neutrophils. Dig Dis Sci (1994) 0.82
Interferon alfa2a induction therapy in combination with ribavirin and amantadine for the treatment of naive patients with chronic HCV infection. J Viral Hepat (2004) 0.82
Effect of cimetidine on digoxin kinetics and creatinine clearance. Am Heart J (1984) 0.82
[Drugs interacting with coumarine oral anticoagulants (author's transl)]. Klin Wochenschr (1973) 0.82
[Determination of digoxin and digitoxin in the blood and their clinical significance]. Klin Wochenschr (1973) 0.81
Absorption of digoxin from the distal parts of the intestine in man. Eur J Clin Pharmacol (1975) 0.81
Diphenylhydantoin: correlation between protein binding and albumin concentration. Klin Wochenschr (1975) 0.81
Ultrasound-guided emergency endoscopic retrograde biliary drainage without radiography. Endoscopy (1997) 0.81
Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klin Wochenschr (1985) 0.80
Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. Clin Pharmacol Ther (1979) 0.80
Simple fluorometric method for estimating practolol (1-(4-aminophenoxy)-3-isopropylaminopropan-2-0l) in blood and urine. Clin Chem (1972) 0.79
Factors predicting the therapeutic outcome of duodenal ulcer treatment with H2-receptor antagonists. Klin Wochenschr (1985) 0.79
Analysis of DNA strand breaks, oxidized bases, and glutathione S-transferase P1 in human colon cells from biopsies. Cancer Epidemiol Biomarkers Prev (1999) 0.79
[Incidence of catechol-O-methyltransferase in human erythrocytes]. Arch Int Pharmacodyn Ther (1973) 0.79
[Frequency of surgery in ulcer after the introduction of H2-blockers]. Dtsch Med Wochenschr (1984) 0.78
[Granulomatous colitis with pseudopolyp in schistosomiasis]. Dtsch Med Wochenschr (1989) 0.78
[Purification and characterization of human placenta S-adenosylmethionine:catechol-O-methyltransferase]. Biochim Biophys Acta (1970) 0.78
Influence of phenobarbital treatment on cimetidine kinetics. Eur J Clin Pharmacol (1981) 0.78
[Hepatic drug interactions]. Fortschr Med (1985) 0.78
[Treatment failure of cimetidine in duodenal ulcer (author's transl)]. Dtsch Med Wochenschr (1982) 0.78
Cimetidine impairs nitrazepam clearance. Clin Pharmacol Ther (1983) 0.77
Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B. Hepatogastroenterology (1999) 0.77
The pharmacokinetic properties of beta adrenoceptor blocking drugs. Arch Int Pharmacodyn Ther (1980) 0.77
Cimetidine pharmacokinetics and dosage requirements in children. Eur J Pediatr (1985) 0.77
Superoxide, hydroxyl and fatty acid radical scavenging by aminosalicylates. Direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol (1992) 0.76
Interaction between metronidazole and drugs eliminated by oxidative metabolism. Clin Pharmacol Ther (1985) 0.76
Clinical pharmacokinetics of hypolipidaemic drugs. Clin Pharmacokinet (1979) 0.76
Cimetidine excretion into breast milk. Br J Clin Pharmacol (1979) 0.76
Cimetidine disposition in obesity. Am J Gastroenterol (1984) 0.76
Altered disposition and availability of cimetidine in liver cirrhotic patients. Br J Clin Pharmacol (1982) 0.75
A prospective randomised trial on the effect of monitoring plasma anticonvulsant levels in epilepsy. J Neurol (1981) 0.75
Different iron-chelating properties of aminosalicylates. Gastroenterology (1992) 0.75
Proceedings: Effect of portosystemic shunting on the distribution of drugs. Arzneimittelforschung (1976) 0.75
Increased bioavailability of cimetidine with age? Eur J Clin Pharmacol (1979) 0.75
Proceedings: Pharmacokinetics of drugs in patients with nephrotic syndrome. Arzneimittelforschung (1976) 0.75
[Studies on the therapeutic scope of valproic acid]. Med Welt (1979) 0.75
[Antiepileptic therapy with valproinic acid. Correlations of side effects and serum levels of valproinic acid]. Fortschr Med (1979) 0.75
Malignant pheochromocytoma. Effect of oral alpha-methyl-p-tyrosine upon catecholamine metabolism. Klin Wochenschr (1979) 0.75
[Drug interactions in therapy using coumarin derivatives]. Internist (Berl) (1979) 0.75
Sensitive fluorometric method for determination of quercetin in plasma or urine. Clin Chem (1973) 0.75
[Letter: Drug interactions]. Dtsch Med Wochenschr (1974) 0.75
[Overnight fall in the serum level of carbamazepine (author's transl)]. Nervenarzt (1979) 0.75
The clinical use of plasma drug concentrations. Ration Drug Ther (1976) 0.75
Beta-adrenoceptor blocking drugs at maximum beta-blockade in relation to dose and plasma concentration. Cardiology (1979) 0.75
Reduced cimetidine clearance with age. N Engl J Med (1979) 0.75